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Abstract
Background: This study was conducted to evaluate the effects of probiotic supplementation on gene expression related to 
inflammation, insulin and lipid in patients with Parkinson’s disease (PD).
Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted in 50 patients with PD as a pilot study. 
Participants were randomly allocated into two groups to take either 8×109 CFU/day probiotic supplements or placebo (n = 25 each 
group, one capsule daily) for 12 weeks. Gene expression related to inflammation, insulin, and lipid was quantified in peripheral 
blood mononuclear cells (PBMC) of PD patients, with RT-PCR method. 
Results: After the 12-week intervention, compared with the placebo, probiotic intake downregulated gene expression of 
interleukin-1 (IL-1) (P = 0.03), IL-8 (P < 0.001) and tumor necrosis factor alpha (TNF-α) (P=0.04) in PBMC of subjects with PD. In 
addition, probiotic supplementation upregulated transforming growth factor beta (TGF-β) (P = 0.02) and peroxisome proliferator-
activated receptor gamma (PPAR-γ) (P = 0.03) in PBMC of subjects with PD compared with the placebo. We did not observe 
any significant effect of probiotic intake on gene expression of low-density lipoprotein receptor (LDLR) and vascular endothelial 
growth factor (VEGF) in PBMC of patients with PD. 
Conclusion: Overall, probiotics supplementation for 12 weeks in PD patients significantly improved gene expression of IL-1, IL-8, 
TNF-α, TGF-β and PPAR-γ, but did not affect gene expression of VEGF and LDLR, and biomarkers of inflammation and oxidative 
stress. 
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Parkinson’s disease (PD) is a disabling pathology that 
has a usually asymmetric onset, and is characterized by 
both motor and non-motor symptoms which affects 
millions of  people worldwide.1 Experimental models 
of  PD proposed that the loss of  dopaminergic neurons 
is extremely due to increased inflammatory cytokines 
especially tumor necrosis factor alpha (TNF-α).2-4 
Furthermore, the modulation of  peroxisome proliferator-
activated receptor gamma (PPAR-γ) activity results in 
neuroprotective impacts on biomarkers of  oxidative 
stress, apoptosis, and neuroinflammation in PD.5 On the 
other hand, dyslipidemia and obesity are well-established 
risk factors for cognitive disturbances and dementia in 
older adults.6 
Epidemiological and experimental studies in human and 
animal models support a general schema which implicates 
the gut microbiota through the microbiome-gut-brain 
axis in the pathogenesis of  common neurodegenerative 
diseases, including PD and Alzheimer’s disease.7,8 In 
addition, depletion or modulation of  the gut microbiota 
can influence the severity of  the central pathology or 
behavioral deficits observed in brain disorders.9 Some 
studies have previously reported the beneficial effects 
of  probiotics on metabolic and genetic diseases related 
to neurodegenerative disorders. Previously, we showed 
that 12 weeks of  probiotic administration in people 
with multiple sclerosis (MS) significantly decreased 
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interleukin 8 (IL-8) and TNF-α gene expressions, but did 
not affect expression of  genes involved in insulin and 
lipid metabolism.10 Furthermore, Steed et al11 revealed 
that 6-month synbiotic supplementation in patients with 
active Crohn’s disease led to a significant reduction in 
TNF-α gene expression. In another study, Hsieh et al12 
observed that reducing levels of  PPAR-γ gene expression 
after high fructose treatment, were significantly elevated 
by Lactobacillus reuteri supplementation in animal models. 
This evidence suggests the importance of  probiotic 
supplementation on biomarkers of  inflammation 
and oxidative stress, and gene expression related to 
inflammation, insulin, and lipid in patients with PD. To 
the best of  our knowledge, data on the effects of  probiotic 
supplementation on biomarkers of  inflammation 
and oxidative stress, and gene expression related to 
inflammation, insulin and lipid in patients with PD are 
limited and controversial. The aim of  the current survey 
was to evaluate the effects of  probiotic supplementation 
on inflammation and oxidative stress biomarkers, and 
gene expression related to inflammation, insulin and lipid 
in patients with PD.
Subjects and Methods
Participants
This randomized, double-blind, placebo-controlled 
clinical trial, registered in the Iranian Registry of  Clinical 
Trials (identifier: IRCT20170513033941N34; http://
www.irct.ir), was conducted among population with PD, 
aged 50–80 years old, diagnosed according to the clinical 
diagnostic criteria of  the UK PD Society Brain Bank13 
and referred to the Shahid Beheshti hospital in Kashan, 
Iran, between October 2017 and January 2018. This 
study was performed according to Good Clinical Practice 
guidelines, and the study protocol was approved by the 
Research Ethics Committee of  Islamic Azad University. 
Written informed consent was obtained from all patients 
before the study. Exclusion criteria were as following: 
taking probiotic and/or synbiotic supplements, taking 
antioxidant supplements and anti-inflammatory agents, 
suffering from depression and severe psychosis, 
hypothyroidism, hyperthyroidism, and being smoker. 
Study Design
At baseline, to decrease potential confounding effects, 
all participants were stratified randomly according to 
age, body mass index (BMI), gender and the dosage 
and kind of  medications. Then, subjects in each block 
were randomly allocated into 2 treatment groups to take 
either 8×109 CFU/day probiotic, containing Lactobacillus 
acidophilus, Bifidobacterium bifidum, L. reuteri, and Lactobacillus 
fermentum (each 2 × 109) (n = 25) or placebo (n = 25) 
for 12 weeks. In addition, all participants were matched 
according to age, BMI, gender, and the dosage and type 
of  medications. Probiotics and placebos were produced 
by Lactocare Zisttakhmir Company (Tehran, Iran) and 
Barij Essence Pharmaceutical Company (Kashan, Iran), 
respectively. Since the supplements and placebo capsules 
had similar packaging, patients and researchers were 
unaware of  the content of  the package until the end 
of  study. Randomization assignment was done using 
computer-generated random numbers as blindness by a 
trained staff  at the neurology clinic. Patients, investigators, 
clinical site staff  and laboratory staff  were all masked to 
treatment assignment throughout the study. All people 
completed 3-d dietary records (2 weeks’ days and one 
weekend day) at weeks 1, 5, 9, and 12 of  the trial. To 
obtain nutrient intakes of  participants according to 3-d 
food records, we applied Nutritionist IV software (First 
Databank, San Bruno, CA) adapted for the Iranian food 
pattern.14 Physical activity was described as metabolic 
equivalents (METs) in hours per day. To determine the 
METs for each subject, we multiplied the times (in hour 
per day) reported for each physical activity by its related 
METs coefficient by standard tables.
Treatment Adherence
Compliance was evaluated by counting the remaining 
supplements and placebos, and subtracting from the 
number of  supplements provided to the participants. To 
increase compliance rate, all subjects received reminder 
messages on their cell phones every day to remind them 
to take their capsules.
Assessment of  Anthropometric Parameters
Weight was measured on a balance scale (Seca, Hamburg, 
Germany) at baseline and after the 12-week intervention 
in the clinic by a trained staff  member. Height was 
determined by a non-stretched tape measure (Seca, 
Hamburg, Germany) to the nearest 0.1 cm. BMI was 
determined as weight in kg divided by height in meters 
squared. 
 
Assessment of  Outcomes
The primary outcome was gene expression related to 
inflammatory markers. The secondary outcome was gene 
expression related to insulin and lipid metabolism, and 
biomarkers of  inflammation and oxidative stress. 
Biochemical Measurements
The nitric oxide (NO) levels were assessed using Griess 
method15 with inter- and intra-assay coefficient variances 
(CVs) of  lower than 5%. Plasma glutathione (GSH) was 
measured using Beutler et al method16 with inter- and 
intra-assay CVs less than 5%. 
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Isolation of  Lymphocyte, RNA Extraction and cDNA 
Synthesis
Twenty milliliters of  blood samples were collected 
in anti-coagulant EDTA tubes. Lymphocytes were 
isolated using 50% percoll solution (Sigma-Aldrich, 
Dorset, UK) gradient by centrifugation for 20 minutes 
and 3000 rpm at 4°C.17 Total RNA was extracted based 
on acid guanidinium-phenol-chloroform procedure 
using RNX™-plus reagent (Cinnacolon, Tehran, Iran) 
according to the manufacturer’s instructions. RNAs was 
treated with DNAase I (Fermentas, Lithuania) to ensure 
the elimination of  any genomic DNA contamination. 
Concentration, integration, and purity of  RNA samples 
were determined by spectrometry and gel electrophoresis. 
Three micrograms of  total RNA was used for cDNA 
synthesis with random hexamer and oligo (dT) 18 
primers through RevertAid™ Reverse Transcriptase 
(Fermantase, Canada) in total 20 μL reaction mixture.17
Real-time PCR Analysis 
Appropriate primers for IL-1, IL-8, TNF-α, transforming 
growth factor beta (TGF-β), vascular endothelial growth 
factor (VEGF), PPAR-γ and LDLR, and glyceraldehyde-3 
phosphate dehydrogenase were designed (Table 
1). Quantitative Real-time PCR was performed by 
LightCycler® 96 sequence detection systems (Roche 
Diagnostics, Rotkreuz, Switzerland) using 4 μL of  5× 
EVA GREEN I master mix (Salise Biodyne, Japan), 10 
ng cDNA, 200 nM of  each forward and reverse primers 
in final volume of  20 μL. PCR was performed through 
the following instruction: an initial denaturation at 95°C 
for 10 minutes, followed by 40 cycles of  denaturation 
at 95°C for 10 seconds, annealing at 54–62.1°C for 15 
seconds and extension at 72°C for 30 seconds. The 
specificity of  PCR products was evaluated by 1.5% 
agarose gel electrophoresis and melting curve analysis. 
All experiments were performed at least in triplicate.
Sample Size
We used a randomized clinical trial sample size formula 
with type one (α) and type 2 errors (β) to be 0.05 and 
the power of  80% to calculate sample size. Based on a 
previous study,10 we used a standard deviation (SD) of 
0.10-fold change and a difference in mean (d) of  0.11-
fold change, considering TNF-α level as the key variable. 
According to the calculations, 21 individuals should be 
enrolled in each group. Assuming a dropout of  4 people 
per group, the final sample size was determined to be 25 
people per group. 
Statistical Methods
To determine whether the study variables were normally 
distributed or not, we used the Kolmogorov-Smirnov 
test. To detect differences in anthropometric measures, 
macro- and micro-nutrient intakes, gene expression 
related to inflammation, insulin, and lipid between 2 
groups, we used Student’s t test to independent samples. 
Adjustment for changes in baseline values of  biochemical 
variables, age and baseline BMI was performed by analysis 
of  covariance (ANCOVA).18 Pearson Chi-square test was 
used for comparison of  categorical variables. The P value 
of  <0.05 were considered statistically significant. For all 
statistical analyses we used the Statistical Package for 
Social Science version 18 (SPSS Inc., Chicago, Illinois, 
USA).
Results
Fifty subjects [probiotic (n = 25) and placebo (n = 25)] 
Table 1. Specific Primers Used for Real-Time Quantitative PCR
Gene Primer Product Size (bp) Annealing  Temperature (C)
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
IL-1 F: GCTTCTCTCTGGTCCTTGG 174 56
R: AGGGCAGGGTAGAGAAGAG






TGF-β F: TTGAGACTTTTCCGTTGCCG 227 56
R: CGAGGTCTGGGGAAAAGTCT
VEGF F: CTTCTGAGTTGCCCAGGAGA 216 54
R: CTCACACACACACAACCAGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
Abbreviations: GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; IL-1, interleukin-1; IL-8, interleukin-8; LDLR, oxidized low-density 
lipoprotein receptor; PPAR-γ, peroxisome proliferator-activated receptor gamma; TNF-α, tumor necrosis factor alpha; TGF-β, transforming 
growth factor beta; VEGF, vascular endothelial growth factor.
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completed the trial (Figure 1). 
Mean age, height, weight and BMI at week 0 and week 
12 of  the intervention were not different between 2 
groups (Table 2).
Based on the 3-day dietary records obtained throughout 
the trial, we found no significant difference in mean 
macro- and micronutrient intakes between 2 groups 
(Data not shown).
Compared with the placebo, probiotic supplementation 
did not affect plasma NO (β 1.66; 95% CI, -1.31, 4.64; 
P = 0.26) and GSH levels (β 9.90; 95% CI, -26.26, 46.06; 
P = 0.58) (Table 3).
After the 12-week intervention, compared with the 



































Figure 1. Summary of patient flow diagram. 
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Figure 1. Summary of Patient Flow Diagram.
Table 2. General Characteristics of Study Participants
Placebo group (n = 25) Probiotic group (n = 25) P1
Gender (%)
Male 16 (64.0) 17 (51.5) 0.76†
Female 9 (36.0) 8 (47.1)
Duration of Parkinson’s disease (y) 5.4 ± 2.5 5.0 ± 1.8 0.57
Levodopa therapy (%) 25 (100.0) 25 (100.0) >0.99†
Amantadine therapy (%) 25 (100.0) 25 (100.0) >0.99†
Age (y) 66.7 ± 10.7 66.9 ± 7.0 0.92
Height (cm) 163.9 ± 5.7 164.2 ± 4.5 0.86
Weight at study baseline (kg) 66.6 ± 6.8 67.6 ± 6.6 0.58
Weight at end-of-trial (kg) 66.5 ± 6.6 67.8 ± 6.5 0.45
BMI at study baseline (kg/m2) 24.8 ± 2.8 25.1 ± 2.9 0.68
BMI at end-of-trial (kg/m2) 24.8 ± 2.7 25.2 ± 2.8 0.57
Data are means ± SDs.
1 Obtained from independent t test. 
† Obtained from Pearson chi-square test.
Table 3. The Effect of Probiotic Supplementation on Biomarkers of Inflammation and Oxidative Stress in Patients With Parkinson’s Disease
Variables
Placebo Group (n = 25) Probiotic Group (n = 25)
Difference in Outcome Measures Between Probiotic and 
Placebo Treatment Groups1
Baseline Week 12 Baseline Week 12 β (95% CI) P2
NO (µmol/L) 47.6 ± 3.2 49.1 ± 4.9 53.5±3.7 54.0±3.6 1.66 (-1.31, 4.64) 0.26
GSH (µmol/L) 603.4 ± 93.7 591.9 ± 70.3 494.9±76.9 522.2±90.0 9.90 (-26.26, 46.06) 0.58
Data are mean ±SDs.
1”Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcomes 
measures between treatment groups (probiotic group = 1 and placebo group = 0)]. 
2 Obtained from ANCOVA (adjusted for baseline values of each biochemical variables, age and baseline BMI).
GSH, total glutathione; NO, nitric oxide.
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of  IL-1 (P = 0.03), IL-8 (P < 0.001) and TNF-α (P = 
0.04) in peripheral blood mononuclear cells) PBMC) of 
subjects with PD (Figure 2). 
Probiotic supplementation upregulated TGF-β (P = 
0.02) in PBMC of  subjects with PD compared with the 
placebo (Figure 2). We did not observe any significant 
effect of  probiotic supplementation on gene expression 
of  VEGF in PBMC of  patients with PD. 
Probiotic intake upregulated PPAR-γ (P = 0.03) in 
PBMC of  subjects with PD compared with the placebo 
(Figure 2). Probiotic supplementation did not affect gene 
expression of  LDLR in PBMC of  patients with PD was 
seen. 
Discussion
In the current investigation, we evaluated the effects of 
probiotic supplementation on gene expression related to 
inflammation, insulin and lipid in individuals with PD. 
We found that probiotic supplementation for 12 weeks 
in populations with PD significantly improved gene 
expression of  IL-1, IL-8, TNF-α, TGF-β and PPAR-γ, 
but did not affect VEGF and LDLR. To the best of  our 
knowledge, this investigation is the first report of  the 
effects of  probiotic supplementation on biomarkers of 
inflammation and oxidative stress, and gene expression 
related to inflammation, insulin and lipid in populations 
with PD.
This study evidenced that probiotic supplementation 
to patients with PD for 12 weeks significantly 
downregulated gene expression levels of  IL-1, IL-8 and 
TNF-α in PBMC compared with the placebo. Earlier, 
we have showed that probiotic supplementation for 
12 weeks to patients with MS significantly decreased 
gene expression levels of  IL-8 and TNF-α; however, it 
did not affect gene expression of  IL-1.10 Furthermore, 
supplementation with Lactobacillus paracasei and L. reuteri 
in an animal model significantly decreased the expression 
of  hepatic IL-1β, IL-6 and TNF-α through suppressing 
the mitogen-activated protein kinase (MAPK) and 
nuclear factor κB (NF-kB) signaling pathways.19 Gene 
expression of  TNF-α, IL-1β and IL-6 was also up-
regulated in intestinal mucositis tissues following the 
treatment with probiotics.20 In another study, Lactobacillus 
plantarum significantly downregulated gene expression 
of  IL-8 and TNF-α in HT-29 cells at 6 hours as well 
as 24 hours.21 Therefore, due to their anti-inflammatory 
and anti-oxidative properties, probiotics may be useful to 
decrease the duration of  neurological symptoms. Unlike, 
gene expression of  TNF-α was not influenced with 
supplementation of  overweight and obese people with 
200 g/d yogurt enriched by L. acidophilus, Bifidobacterium 
BB12 and Lactobacillus casei for 8 weeks.22 Taking probiotic 
capsules for 8 weeks by patients with rheumatoid arthritis 
decreased hs-CRP, but did not influence NO levels.23 In 
addition, NO production was not changed in the groups 
treated with probiotic in herpes simplex virus type 1.24 
Different study designs, lack of  considering baseline 
levels of  biochemical variables, different dosages and 
types of  probiotic strains as well as duration of  the 
intervention might provide some reasons for discrepant 
findings. Increased inflammatory markers are associated 
with increased microglia activation, which in turn would 
result in neurodegeneration through the release of  free 
radicals, pro-inflammatory, immunomodulatory and 
anti-inflammatory cytokines.25 The dysfunctions in the 
immune system in terms of  inflammatory cytokines 
production are intimately related to the nervous system 
alterations; therefore, controlling inflammatory markers 
may ameliorate the central inflammation and recovers 
the nervous system functions.26 Probiotic intake may 
decrease gene expression levels of  inflammatory markers 
through modulating toll-like receptors, NF-kB and 
MAPK pathways.27 







































































































































Figure 2. Effect of a 12-week supplementation with probiotic or placebo on gene expression of IL-1, IL-8, TNF-α, TGF-β, VEGF, PPAR-γ and LDLR in PBMC of patients with 
Parkinson's disease.  
IL-1, interleukin-1; IL-8, interleukin-8; LDLR, oxidized low-density lipoprotein; PBMC, peripheral blood mononuclear cells; PPAR-γ, peroxisome proliferator-activated receptor 





Figure 2. Effect of a 12-Week Supplementation With probiotic or placebo on Gene Expression of IL-1, IL-8, TNF-α, TGF-β, VEGF, PPAR-γ and LDLR in PBMC 
of Patients With Parkinson’s Disease. 
IL-1, interleukin-1; IL-8, interleukin-8; LDLR, oxidized low-density lipoprotein; PBMC, peripheral blood mononuclear cells; PPAR-γ, peroxisome proliferator-
activated receptor gamma; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor.
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weeks in people with PD upregulated gene expression 
of  PPAR-γ in PBMC compared with the placebo, but did 
not affect gene expression of  LDLR. Few animal and cell 
line studies have reported some effects of  probiotics on 
gene expression levels of  PPAR-γ and LDLR. In a study 
by Liu et al,28 it was seen that L. reuteri could improve 
the gut health of  neonatal piglets by increasing colonic 
butyric acid levels and up-regulating the downstream 
molecules of  butyric acid and PPAR-γ. In addition, L. 
casei supplementation in a rat model of  acute liver failure 
significantly increased gene expression of  PPAR-γ.29 
Such beneficial effects of  probiotic supplementation 
on signaling pathway related to insulin metabolism was 
not reported by others. For instance, gene expression of 
PPAR-γ was downregulated after the intake of  probiotics 
in rat models.30 Dolatkhah et al31 found that a 6-week 
probiotics supplementation to women with gestational 
diabetes mellitus did not influence insulin metabolism. 
Abnormal signaling pathway related to insulin 
metabolism in people with PD may be correlated with 
extracellular events of  relevance to neurodegeneration, 
inflammation and oxidative damage, which in turn 
is increasingly recognized as a main contributor to 
the pathogenesis of  PD.32 Therefore, probiotics due 
to their beneficial effects on insulin metabolism may 
decrease metabolic events related to diabetes and 
cardiovascular diseases in patients with PD. PPAR-γ 
plays a key function in the regulation of  metabolism, 
including regulating insulin sensitivity, mitochondrial 
biogenesis, and carbohydrate and lipid homoeostasis.33,34 
In addition, it was reported that PPAR-γ has potential 
beneficial effects in a number of  neurological disorders, 
such as PD, Alzheimer’s disease and amyotrophic lateral 
sclerosis.35 Also, simultaneous targeting of  dysfunctional 
pathways may underlie the potent neuroprotective 
activity displayed by PPAR-γ agonists.35 Probiotics 
intake may improve signaling pathway related to insulin 
metabolism by reducing cytokines and inhibiting the NF-
kB pathway36 and gut microbiota-short chain fatty acids-
hormone axis.37
The current study had a number of  strengths. Firstly, 
we focused on some interesting questions using a 
randomized, double-blind, placebo-controlled trial. 
The findings of  improved gene expression related to 
inflammation and insulin in the probiotic group in our 
study are interesting, but need to be confirmed in a larger 
study. Another strength of  the current study was the 
absence of  dropout rate.
 The current study had few limitations. In this study, 
due to funding limitations, we did not characterize 
the microbiota and thus could not establish whether 
probiotic intake over 12 weeks changed its composition. 
In addition, evaluating protein levels would have been 
more relevant. Unfortunately, we did not assess the 
effects of  probiotic supplementation on protein levels.
Overall, probiotics supplementation for 12 weeks 
in PD patients significantly improved gene expression 
of  IL-1, IL-8, TNF-α, TGF-β and PPAR-γ, but did 
not affect gene expression of  VEGF and LDLR, 
and biomarkers of  inflammation and oxidative stress. 
This suggests probiotic supplementation may confer 
advantageous therapeutic potential for people with PD. 
Further research is needed in other participants and for 
longer periods to determine the safety and beneficial 
effects of  probiotic supplementation. Moreover, further 
studies should measure gene expression levels related to 
oxidative stress.
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